Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen

O. Klein; S. Linn; C. Davidson; A. Hadary; A. Shukha; J. Zidan; A. Eitan; A. I. Kook

doi:10.1054/brst.2002.0477

Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen

O. Klein, S. Linn, C. Davidson, A. Hadary, A. Shukha, J. Zidan, A. Eitan, A. I. Kook

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Early detection is crucial for successful treatment of all types of cancer. The specificity and sensitivity of the current methods vary from 50% to 80%. The use of specific tumor antigens and cytometric technology has resulted in the development of a new procedure for the early detection of breast tumors. This new method is reported. The test utilizes static cytometry, which records polarization and intensity changes in fluorescent light emitted from each individual lymphocyte obtained from tumor-bearing patients stimulated by the relevant specific tumor antigen. Using MUC-1/SEC as the specific antigen, we detected breast tumors with 85% specificity and 81% sensitivity in 137 breast tumor-bearing women. A significant linear correlation was found between the SCM test and the conventional classification of relative risk for breast cancer in benign lesions, suggesting that this is a precise method that could be used in mass screening for early detection of breast cancer.

Original language	English
Pages (from-to)	478-483
Number of pages	6
Journal	Breast
Volume	11
Issue number	6
DOIs	https://doi.org/10.1054/brst.2002.0477
State	Published - Dec 2002
Externally published	Yes

Bibliographical note

Funding Information:
*The work was supported by the Israel Association for the Fight Against Cancer #9600210 and #9720282. Address correspondence to: Dr A. I. Kook, Research Department, Sieff Government Hospit al, Safed 13100, Israel. Tel.: +972 6 682 8091; Fax: + 972 6 692 3753; E-mail: [email protected] Received: 24 July 2002 Revised: 13 August 2002 Accepted: 28 August 2002

Funding

*The work was supported by the Israel Association for the Fight Against Cancer #9600210 and #9720282. Address correspondence to: Dr A. I. Kook, Research Department, Sieff Government Hospit al, Safed 13100, Israel. Tel.: +972 6 682 8091; Fax: + 972 6 692 3753; E-mail: [email protected] Received: 24 July 2002 Revised: 13 August 2002 Accepted: 28 August 2002

Funders	Funder number
Israel Association for the Fight Against Cancer	9720282, 9600210

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1054/brst.2002.0477

Fingerprint

Dive into the research topics of 'Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen'. Together they form a unique fingerprint.

Cite this

Klein, O., Linn, S., Davidson, C., Hadary, A., Shukha, A., Zidan, J., Eitan, A., & Kook, A. I. (2002). Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen. Breast, 11(6), 478-483. https://doi.org/10.1054/brst.2002.0477

@article{30cb42e1e4034be2a316d2e7aec8f155,

title = "Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen",

abstract = "Early detection is crucial for successful treatment of all types of cancer. The specificity and sensitivity of the current methods vary from 50% to 80%. The use of specific tumor antigens and cytometric technology has resulted in the development of a new procedure for the early detection of breast tumors. This new method is reported. The test utilizes static cytometry, which records polarization and intensity changes in fluorescent light emitted from each individual lymphocyte obtained from tumor-bearing patients stimulated by the relevant specific tumor antigen. Using MUC-1/SEC as the specific antigen, we detected breast tumors with 85% specificity and 81% sensitivity in 137 breast tumor-bearing women. A significant linear correlation was found between the SCM test and the conventional classification of relative risk for breast cancer in benign lesions, suggesting that this is a precise method that could be used in mass screening for early detection of breast cancer.",

author = "O. Klein and S. Linn and C. Davidson and A. Hadary and A. Shukha and J. Zidan and A. Eitan and Kook, {A. I.}",

note = "Funding Information: *The work was supported by the Israel Association for the Fight Against Cancer #9600210 and #9720282. Address correspondence to: Dr A. I. Kook, Research Department, Sieff Government Hospit al, Safed 13100, Israel. Tel.: +972 6 682 8091; Fax: + 972 6 692 3753; E-mail: [email protected] Received: 24 July 2002 Revised: 13 August 2002 Accepted: 28 August 2002",

year = "2002",

month = dec,

doi = "10.1054/brst.2002.0477",

language = "אנגלית",

volume = "11",

pages = "478--483",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "6",

}

Klein, O, Linn, S, Davidson, C, Hadary, A, Shukha, A, Zidan, J, Eitan, A & Kook, AI 2002, 'Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen', Breast, vol. 11, no. 6, pp. 478-483. https://doi.org/10.1054/brst.2002.0477

Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen. / Klein, O.; Linn, S.; Davidson, C. et al.
In: Breast, Vol. 11, No. 6, 12.2002, p. 478-483.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen

AU - Klein, O.

AU - Linn, S.

AU - Davidson, C.

AU - Hadary, A.

AU - Shukha, A.

AU - Zidan, J.

AU - Eitan, A.

AU - Kook, A. I.

N1 - Funding Information: *The work was supported by the Israel Association for the Fight Against Cancer #9600210 and #9720282. Address correspondence to: Dr A. I. Kook, Research Department, Sieff Government Hospit al, Safed 13100, Israel. Tel.: +972 6 682 8091; Fax: + 972 6 692 3753; E-mail: [email protected] Received: 24 July 2002 Revised: 13 August 2002 Accepted: 28 August 2002

PY - 2002/12

Y1 - 2002/12

N2 - Early detection is crucial for successful treatment of all types of cancer. The specificity and sensitivity of the current methods vary from 50% to 80%. The use of specific tumor antigens and cytometric technology has resulted in the development of a new procedure for the early detection of breast tumors. This new method is reported. The test utilizes static cytometry, which records polarization and intensity changes in fluorescent light emitted from each individual lymphocyte obtained from tumor-bearing patients stimulated by the relevant specific tumor antigen. Using MUC-1/SEC as the specific antigen, we detected breast tumors with 85% specificity and 81% sensitivity in 137 breast tumor-bearing women. A significant linear correlation was found between the SCM test and the conventional classification of relative risk for breast cancer in benign lesions, suggesting that this is a precise method that could be used in mass screening for early detection of breast cancer.

AB - Early detection is crucial for successful treatment of all types of cancer. The specificity and sensitivity of the current methods vary from 50% to 80%. The use of specific tumor antigens and cytometric technology has resulted in the development of a new procedure for the early detection of breast tumors. This new method is reported. The test utilizes static cytometry, which records polarization and intensity changes in fluorescent light emitted from each individual lymphocyte obtained from tumor-bearing patients stimulated by the relevant specific tumor antigen. Using MUC-1/SEC as the specific antigen, we detected breast tumors with 85% specificity and 81% sensitivity in 137 breast tumor-bearing women. A significant linear correlation was found between the SCM test and the conventional classification of relative risk for breast cancer in benign lesions, suggesting that this is a precise method that could be used in mass screening for early detection of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036916613&partnerID=8YFLogxK

U2 - 10.1054/brst.2002.0477

DO - 10.1054/brst.2002.0477

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0036916613

SN - 0960-9776

VL - 11

SP - 478

EP - 483

JO - Breast

JF - Breast

IS - 6

ER -

Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this